Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica, a leader in cell and gene therapy, announced a total of 105,923,083 voting rights as of October 31, 2024. This figure is significant for shareholders to assess their stakes in the company. OXB continues to drive innovation in viral vector manufacturing, collaborating with top pharmaceutical firms globally.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
